On June 30, 2025, Cidara Therapeutics (CDTX, Financial) received a reaffirmation from JMP Securities regarding its stock performance outlook. Analyst Roy Buchanan maintained a "Market Outperform" rating for the company. This indicates a continuation of positive sentiment towards Cidara Therapeutics' stock amidst the current market conditions.
Additionally, JMP Securities upheld its price target for Cidara Therapeutics (CDTX, Financial) at $59.00 USD. This price target has remained steady, showing no change from previous assessments by the same analyst. Such consistency may suggest confidence in Cidara Therapeutics' long-term potential and financial health from the perspective of JMP Securities.
The healthcare company, known for its innovative work in therapeutic solutions, continues to be a point of interest in the market. Investors are likely to watch CDTX closely following this reaffirmation of its stock performance expectations and price target by a reputed financial institution.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 7 analysts, the average target price for Cidara Therapeutics Inc (CDTX, Financial) is $68.00 with a high estimate of $140.00 and a low estimate of $35.00. The average target implies an upside of 37.42% from the current price of $49.49. More detailed estimate data can be found on the Cidara Therapeutics Inc (CDTX) Forecast page.
Based on the consensus recommendation from 8 brokerage firms, Cidara Therapeutics Inc's (CDTX, Financial) average brokerage recommendation is currently 1.6, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Cidara Therapeutics Inc (CDTX, Financial) in one year is $0.08, suggesting a downside of 99.84% from the current price of $49.485. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Cidara Therapeutics Inc (CDTX) Summary page.
